reportingrisk.com← the monitorSEC reporting failures, scored and checked against what happened next

Or browse all companies A–Z.

Eloxx Pharmaceuticals, Inc.

ELOX · Nasdaq

No reporting failures in the last 12 months

It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.

—public float
2025-08-14most recent failure

Score over time

01234202220232024202520262022-10-01 · score 12022-07-15 auditor change2023-01-01 · score 12022-07-15 auditor change2023-04-01 · score 12022-07-15 auditor change2023-07-01 · score 12022-07-15 auditor change2024-07-01 · score 22024-05-15 filed late (10-Q) · auditor2024-04-01 filed late (10-K) · auditor2024-10-01 · score 32024-08-14 filed late (10-Q) · auditor2024-05-15 filed late (10-Q) · auditor2024-04-01 filed late (10-K) · auditor2025-01-01 · score 42024-11-19 filed late (10-Q) · auditor2024-08-14 filed late (10-Q) · auditor2024-05-15 filed late (10-Q) · auditor2024-04-01 filed late (10-K) · auditor2025-04-01 · score 42024-11-19 filed late (10-Q) · auditor2024-08-14 filed late (10-Q) · auditor2024-05-15 filed late (10-Q) · auditor2024-04-01 filed late (10-K) · auditor2025-07-01 · score 42025-05-15 filed late (10-Q) · auditor2025-04-01 filed late (10-K) · auditor2024-11-19 filed late (10-Q) · auditor2024-08-14 filed late (10-Q) · auditor2025-10-01 · score 42025-08-14 filed late (10-Q) · auditor2025-05-15 filed late (10-Q) · auditor2025-04-01 filed late (10-K) · auditor2024-11-19 filed late (10-Q) · auditor2026-01-01 · score 32025-08-14 filed late (10-Q) · auditor2025-05-15 filed late (10-Q) · auditor2025-04-01 filed late (10-K) · auditor2026-04-01 · score 32025-08-14 filed late (10-Q) · auditor2025-05-15 filed late (10-Q) · auditor2025-04-01 filed late (10-K) · auditor2026-07-01 · score 12025-08-14 filed late (10-Q) · auditor

Hover or tap a dot to see the filings behind that score.

Why they said they were late

As previously reported by Eloxx Pharmaceuticals, Inc. (the “Company”) in its Form 12b-25 (NT 10-K) filed with the Securities and Exchange Commission on April 1, 2025 and on April 1, 2024, the Company was not able to file its Annual Reports on Form 10-K for the fiscal years ended December 31, 2004 and 2023 because the Company was unable to allocate the financial resources necessary to engage its independent public accounting firm to perform audits of the Company’s financial statements for the years ended December 31, 2024 and 2023 to be included in the Form 10-K for each of those years. Such financial constraints are ongoing, and the Company is unable to engage its independent public accounting firm to conduct a review of the unaudited condensed consolidated financial statements (the “Second Quarter Financial Statements”) to be included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Form 10-Q”). Therefore, the Company is unable to File the Form 10-Q within the prescribed time period without unreasonable effort at expense

NT 10-Q, filed 2025-08-14 · auditor

What it filed

2025-08-14filed late (10-Q)auditor SEC →

As previously reported by Eloxx Pharmaceuticals, Inc. (the “Company”) in its Form 12b-25 (NT 10-K) filed with the Securities and Exchange Commission on April 1, 2025 and on April 1, 2024, the Company was not able to file its Annual Reports on Form 10-K for the fiscal years ended December 31, 2004 and 2023 because the Company was unable to allocate the financial resources necessary to engage its independent public accounting firm to perform audits of the Company’s financial statements for the years ended December 31, 2024 and 2023 to be included in the Form 10-K for each of those years. Such financial constraints are ongoing, and the Company is unable to engage its independent public accounting firm to conduct a review of the unaudited condensed consolidated financial statements (the “Second Quarter Financial Statements”) to be included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the “Form 10-Q”). Therefore, the Company is unable to File the Form 10-Q within the prescribed time period without unreasonable effort at expense

2025-05-15filed late (10-Q)auditor SEC →

As previously reported by Eloxx Pharmaceuticals, Inc. (the “Company”) in its Form 12b-25 (NT 10-K) filed with the Securities and Exchange Commission on April 1, 2025 and on April 1, 2024, the Company was not able to file its Annual Reports on Form 10-K for the fiscal years ended December 31, 2004 and 2023 because the Company was unable to allocate the financial resources necessary to engage its independent public accounting firm to perform audits of the Company’s financial statements for the years ended December 31, 2024 and 2023 to be included in the Form 10-K for each of those years. Such financial constraints are ongoing, and the Company is unable to engage its independent public accounting firm to conduct a review of the unaudited condensed consolidated financial statements (the “First Quarter Financial Statements”) to be included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025 (the “Form 10-Q”). Therefore, the Company is unable to File the Form 10-Q within the prescribed time period without unreasonable effort at expense

2025-04-01filed late (10-K)auditor SEC →

As previously reported by Eloxx Pharmaceuticals, Inc. (the “Company”) in its Form 12b-25 (NT 10-K) filed with the Securities and Exchange Commission on April 1, 2024, the Company was not able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 because the Company was unable to allocate the financial resources necessary to engage its independent public accounting firm to perform an audit of the Company’s financial statements for the year ended December 31, 2023 (the “2023 Financial Statements”) to be included in the Form 10-K. Such financial constraints are ongoing, and the Company is unable to engage its independent public accounting firm to conduct an audit of the consolidated financial statements for the year ended December 31, 2024, to be included in the Annual Report on Form 10-K for the year ended December 31, 2024 within the prescribed time period because the Company is currently unable to allocate the financial resources necessary to engage its independent public accounting firm to perform an audit of the Company’s financial statements for the year ended December 31, 2024 (the “2024 Financial Statements”) to be included in the Form 10-K. The Company cannot predict at this time if and when the audit of the 2024 Financial Statements will be completed and if and when it will file the Form 10-K

2024-11-19filed late (10-Q)auditor SEC →

As previously reported by Eloxx Pharmaceuticals, Inc. (the “Company”) in its Form 12b-25 (NT 10-K) filed with the Securities and Exchange Commission on April 1, 2024, the Company was not able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) because the Company was unable to allocate the financial resources necessary to engage its independent public accounting firm to perform an audit of the Company’s financial statements for the year ended December 31, 2023 (the “2023 Financial Statements”) to be included in the Form 10-K. Such financial constraints are ongoing, and the Company is unable to engage its independent public accounting firm to conduct a review of the unaudited condensed consolidated financial statements (the “Third Quarter Financial Statements”) to be included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 (the “Form 10-Q”). Therefore, the Company is unable to File the Form 10-Q within the prescribed time period without unreasonable effort at expense. The Company cannot predict at this time if and when the review of the Third Quarter Financial Statements will be completed and if and when it will file the Form 10-Q

2024-08-14filed late (10-Q)auditor SEC →

As previously reported by Eloxx Pharmaceuticals, Inc. (the “Company”) in its Form 12b-25 (NT 10-K) filed with the Securities and Exchange Commission on April 1, 2024, the Company was not able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) because the Company was unable to allocate the financial resources necessary to engage its independent public accounting firm to perform an audit of the Company’s financial statements for the year ended December 31, 2023 (the “2023 Financial Statements”) to be included in the Form 10-K. Such financial constraints are ongoing, and the Company is unable to engage its independent public accounting firm to conduct a review of the unaudited condensed consolidated financial statements (the “Second Quarter Financial Statements”) to be included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024 (the “Form 10-Q”). Therefore, the Company is unable to File the Form 10-Q within the prescribed time period without unreasonable effort at expense. The Company cannot predict at this time if and when the review of the Second Quarter Financial Statements will be completed and if and when it will file the Form 10-Q

2024-05-15filed late (10-Q)auditor SEC →

As previously reported by Eloxx Pharmaceuticals, Inc. (the “Company”) in its Form 12b-25 (NT 10-K) filed with the Securities and Exchange Commission on April 1, 2024, the Company was not able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) because the Company was unable to allocate the financial resources necessary to engage its independent public accounting firm to perform an audit of the Company’s financial statements for the year ended December 31, 2023 (the “2023 Financial Statements”) to be included in the Form 10-K. Such financial constraints are ongoing, and the Company is unable to engage its independent public accounting firm to conduct a review of the unaudited condensed consolidated financial statements (the “First Quarter Financial Statements”) to be included in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 (the “Form 10-Q”). Therefore, the Company is unable to File the Form 10-Q within the prescribed time period without unreasonable effort at expense. The Company cannot predict at this time if and when the review of the First Quarter Financial Statements will be completed and if and when it will file the Form 10-Q

2024-04-01filed late (10-K)auditor SEC →

Eloxx Pharmaceuticals, Inc. (the “Company”) will not be able to file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”) within the prescribed time period because the Company is currently unable to allocate the financial resources necessary to engage its independent public accounting firm to perform an audit of the Company’s financial statements for the year ended December 31, 2023 (the “2023 Financial Statements”) to be included in the Form 10-K. The Company cannot predict at this time if and when the audit of the 2023 Financial Statements will be completed and if and when it will file the Form 10-K

2022-07-15auditor changed or resigned SEC →

About this score

reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.

Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.

See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.

Every item above is a filing this company made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not investment advice

reportingrisk.com← back to the monitorAll companies A-Z · RSS · found an error? hello@reportingrisk.com